Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_4

33%

Ph not_applicable

33%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 4Post-market surveillance

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Detailed Status

Completed2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (33.3%)

Phase 41 (33.3%)

N/A1 (33.3%)

Trials by Status

completed267%

recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_4

Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

NCT00004317

completedphase_1

A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea

NCT00000980

completednot_applicable

Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients

NCT00002062

Clinical Trials (3)

Showing 3 of 3 trials

NCT00004317Phase 4

Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

Recruiting

NCT00000980Phase 1

A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea

Completed

NCT00002062Not Applicable

Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3